-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a real-world study was published in the journal BMC Cancer to evaluate the effect of durvalumab treatment on the prognosis of patients with locally advanced non-small cell lung cancer (LA-NSCLC) after chemoradiotherapy
Recently, a real-world study was published in the journal BMC Cancer to evaluate the effect of durvalumab treatment on the prognosis of patients with locally advanced non-small cell lung cancer (LA-NSCLC) after chemoradiotherapy
Of the 68 patients included in the study, none received induction chemotherapy, and 50 (73.
Of the 68 patients included in the study, none received induction chemotherapy, and 50 (73.
During a median follow-up of 14.
During a median follow-up of 14.
Multivariate analysis showed that the use of durvalumab significantly reduced the hazard ratio (HR) of DMFS, PFS and OS (HR 0.
Multivariate analysis showed that the use of durvalumab significantly reduced the hazard ratio (HR) of DMFS, PFS and OS (HR 0.
There was no significant difference in DMFS, PFS and OS between stage IIIA and IIIB-IIIC (HR = 1.
There was no significant difference in DMFS, PFS and OS between stage IIIA and IIIB-IIIC (HR = 1.
Taken together, studies have shown that durvalumab treatment following chemoradiotherapy in locally advanced non-small cell lung cancer (LA-NSCLC) improves patient outcomes
Original source:
Original source:Yamamoto T, Tsukita Y, Katagiri Y, Matsushita H, Umezawa R, Ishikawa Y, Takahashi N, Suzuki Y, Takeda K, Miyauchi E, Saito R, Katsuta Y, Kadoya N, Jingu K.
Yamamoto T, Tsukita Y, Katagiri Y, Matsushita H, Umezawa R, Ishikawa Y, Takahashi N, Suzuki Y, Takeda K, Miyauchi E, Saito R, Katsuta Y, Kadoya N, Jingu K.
Durvalumab after chemoradiotherapy for locally advanced non- small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.
BMC Cancer.
2022 Apr 4;22(1):364.
doi: 10.
1186/s12885-022-09354-1.
PMID: 35379201.
Leave a message here
